BTIG Initiates Coverage of ORIC Pharmaceuticals at Buy
Fintel reports that on September 23, 2026, BTIG initiated coverage of ORIC Pharmaceuticals (NASDAQGS:ORIC) (DB:4TZ) with a Buy recommendation.
ORIC Pharmaceuticals, Inc., based in the United States, operates within the biotechnology sector, primarily focusing on the development of treatments aimed at overcoming resistance mechanisms in cancer. The company has undertaken significant projects targeting multiple resistance pathways with its flagship programs including ORIC-101 and ORIC-533. ORIC-101, which targets the glucocorticoid receptor, is advancing through clinical trials to tackle solid tumors. ORIC-533, an orally bioavailable small molecule inhibiting CD73, is designed to enhance immune response against tumors. ORIC Pharmaceuticals leverages a science-driven approach to address therapeutic resistance and relapse, positioning itself in critical areas of oncology research and addressing unmet medical needs in cancer treatment.
Prior to the rating action, the stock closed at $13.50 on September 22, 2026. This latest close of $13.50 represents a price change of +9.22% over one week from a baseline close of $12.36 on September 15, 2026, and a price change of -4.93% over one month from a baseline close of $14.20 on August 21, 2026. In its latest earnings report on August 3, 2026, ORIC Pharmaceuticals reported an actual EPS of -0.38 compared to an estimated EPS of -0.3687. The company reported actual revenue of $0.00, which was in line with the estimated revenue of $0.00.
As of September 15, 2026, the current consensus target mean for the stock was $20.86, with a median target of $21.42, representing an implied change of +54.55%. This consensus target mean was unchanged from the prior consensus target mean of $20.86 recorded on August 28, 2026, showing a consensus target revision of 0.00%. For the current recommendation period of September 1, 2026, the aggregate analyst recommendations consisted of 8 strong buy, 10 buy, 2 hold, 0 sell, and 0 strong sell recommendations, totaling 20 recommendations. This represents 90.0% positive, 10.0% hold, and 0.0% negative recommendations. In the prior period of August 1, 2026, there were 9 strong buy, 10 buy, 2 hold, 0 sell, and 0 strong sell recommendations, totaling 21 recommendations, which represented 90.5% positive, 9.5% hold, and 0.0% negative recommendations.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 23, 2026 | BTIG | Buy | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.